List of Aristada drug patents

Aristada is owned by Alkermes Inc.

Aristada contains Aripiprazole Lauroxil.

Aristada has a total of 13 drug patents out of which 0 drug patents have expired.

Aristada was authorised for market use on 05 October, 2015.

Aristada is available in suspension, extended release;intramuscular dosage forms.

Aristada can be used as treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection, treatment of schizophrenia, treatment of schizophrenia by rapid and continuous intramuscular injection.

The generics of Aristada are possible to be released after 06 April, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(9 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(9 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(10 years from now)

US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(10 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11406632 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic